Rock Springs Capital Management LP Buys 4,000 Shares of Jazz Pharmaceuticals PLC $JAZZ

Rock Springs Capital Management LP grew its stake in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) by 228.6% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 5,750 shares of the specialty pharmaceutical company’s stock after acquiring an additional 4,000 shares during the period. Rock Springs Capital Management LP’s holdings in Jazz Pharmaceuticals were worth $1,087,000 at the end of the most recent quarter.

Other institutional investors also recently made changes to their positions in the company. LRI Investments LLC acquired a new position in shares of Jazz Pharmaceuticals in the fourth quarter valued at approximately $38,000. Danske Bank A S acquired a new stake in Jazz Pharmaceuticals during the 3rd quarter worth approximately $40,000. Geneos Wealth Management Inc. boosted its stake in Jazz Pharmaceuticals by 57.6% in the 1st quarter. Geneos Wealth Management Inc. now owns 375 shares of the specialty pharmaceutical company’s stock valued at $47,000 after purchasing an additional 137 shares during the period. Caitong International Asset Management Co. Ltd boosted its stake in Jazz Pharmaceuticals by 1,383.3% in the 3rd quarter. Caitong International Asset Management Co. Ltd now owns 356 shares of the specialty pharmaceutical company’s stock valued at $47,000 after purchasing an additional 332 shares during the period. Finally, Leonteq Securities AG acquired a new position in Jazz Pharmaceuticals in the 4th quarter valued at $50,000. Institutional investors own 89.14% of the company’s stock.

Jazz Pharmaceuticals Stock Performance

NASDAQ JAZZ opened at $255.43 on Tuesday. The firm’s 50 day simple moving average is $237.89 and its 200 day simple moving average is $204.06. The firm has a market capitalization of $16.05 billion, a price-to-earnings ratio of -12,765.12, a P/E/G ratio of 0.22 and a beta of 0.32. The company has a current ratio of 2.04, a quick ratio of 1.85 and a debt-to-equity ratio of 0.95. Jazz Pharmaceuticals PLC has a 1 year low of $105.00 and a 1 year high of $257.00.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings data on Tuesday, March 31st. The specialty pharmaceutical company reported $6.34 EPS for the quarter. Jazz Pharmaceuticals had a net margin of 0.66% and a return on equity of 14.56%. The business had revenue of $1.07 billion during the quarter. As a group, research analysts expect that Jazz Pharmaceuticals PLC will post 21.9 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several research firms have weighed in on JAZZ. Royal Bank Of Canada increased their price objective on Jazz Pharmaceuticals from $195.00 to $258.00 and gave the stock an “outperform” rating in a research report on Wednesday, May 6th. UBS Group upgraded shares of Jazz Pharmaceuticals from a “neutral” rating to a “buy” rating and upped their price target for the company from $188.00 to $307.00 in a research note on Tuesday, May 19th. Deutsche Bank Aktiengesellschaft raised their price target on shares of Jazz Pharmaceuticals from $250.00 to $270.00 and gave the stock a “buy” rating in a research report on Thursday, July 9th. Sanford C. Bernstein reiterated a “market perform” rating on shares of Jazz Pharmaceuticals in a research note on Tuesday, June 9th. Finally, Canaccord Genuity Group assumed coverage on shares of Jazz Pharmaceuticals in a report on Thursday, July 16th. They issued a “buy” rating and a $290.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, sixteen have issued a Buy rating and three have assigned a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $259.06.

Insider Buying and Selling

In related news, EVP Neena M. Patil sold 1,200 shares of the company’s stock in a transaction on Wednesday, June 10th. The stock was sold at an average price of $231.83, for a total transaction of $278,196.00. Following the completion of the sale, the executive vice president directly owned 51,549 shares in the company, valued at $11,950,604.67. This represents a 2.27% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, Director Bruce C. Cozadd sold 6,000 shares of the firm’s stock in a transaction dated Wednesday, July 1st. The shares were sold at an average price of $240.47, for a total value of $1,442,820.00. Following the completion of the sale, the director directly owned 366,682 shares in the company, valued at $88,176,020.54. This trade represents a 1.61% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last 90 days, insiders have sold 13,098 shares of company stock worth $3,131,906. 4.10% of the stock is owned by company insiders.

About Jazz Pharmaceuticals

Jazz Pharmaceuticals plc is a global biopharmaceutical company focused on developing and commercializing therapies in neuroscience and oncology. The company’s research and development efforts target unmet medical needs in sleep disorders, hematologic malignancies, rare neurological conditions and solid tumors. Jazz’s product portfolio includes therapies for narcolepsy, hepatic veno-occlusive disease, acute myeloid leukemia and other serious disorders.

Flagship products from Jazz Pharmaceuticals include Xyrem® (sodium oxybate) and Xywav® (calcium, magnesium, potassium, and sodium oxybates) for the treatment of cataplexy and excessive daytime sleepiness in patients with narcolepsy.